Shepherd Susan J, Parker Francis C, Muir Jane G, Gibson Peter R
Department of Gastroenterology and Monash University Department of Medicine, Box Hill Hospital, Victoria, Australia.
Clin Gastroenterol Hepatol. 2008 Jul;6(7):765-71. doi: 10.1016/j.cgh.2008.02.058. Epub 2008 May 5.
BACKGROUND & AIMS: Observational studies suggest dietary fructose restriction might lead to sustained symptomatic response in patients with irritable bowel syndrome (IBS) and fructose malabsorption. The aims of this study were first to determine whether the efficacy of this dietary change is due to dietary fructose restriction and second to define whether symptom relief was specific to free fructose or to poorly absorbed short-chain carbohydrates in general.
The double-blinded, randomized, quadruple arm, placebo-controlled rechallenge trial took place in the general community. The 25 patients who had responded to dietary change were provided all food, low in free fructose and fructans, for the duration of the study. Patients were randomly challenged by graded dose introduction of fructose, fructans, alone or in combination, or glucose taken as drinks with meals for maximum test period of 2 weeks, with at least 10-day washout period between. For the main outcome measures, symptoms were monitored by daily diary entries and responses to a global symptom question.
Seventy percent of patients receiving fructose, 77% receiving fructans, and 79% receiving a mixture reported symptoms were not adequately controlled, compared with 14% receiving glucose (P < or = 0.002, McNemar test). Similarly, the severity of overall and individual symptoms was significantly and markedly less for glucose than other substances. Symptoms were induced in a dose-dependent manner and mimicked previous IBS symptoms.
In patients with IBS and fructose malabsorption, dietary restriction of fructose and/or fructans is likely to be responsible for symptomatic improvement, suggesting efficacy is due to restriction of poorly absorbed short-chain carbohydrates in general.
观察性研究表明,限制饮食中的果糖可能会使肠易激综合征(IBS)和果糖吸收不良患者产生持续的症状缓解。本研究的目的一是确定这种饮食改变的疗效是否归因于饮食中果糖的限制,二是确定症状缓解是特定于游离果糖还是一般的吸收不良的短链碳水化合物。
这项双盲、随机、四臂、安慰剂对照的再激发试验在普通社区进行。25名对饮食改变有反应的患者在研究期间食用所有低游离果糖和果聚糖的食物。患者通过分级剂量单独或联合引入果糖、果聚糖,或在进餐时饮用葡萄糖进行随机激发,最长试验期为2周,期间至少有10天的洗脱期。对于主要结局指标,通过每日日记记录和对整体症状问题的回答来监测症状。
接受果糖的患者中有70%、接受果聚糖的患者中有77%、接受混合物的患者中有79%报告症状未得到充分控制,而接受葡萄糖的患者中这一比例为14%(McNemar检验,P≤0.002)。同样,葡萄糖组的整体和个体症状严重程度明显低于其他物质组。症状呈剂量依赖性诱发,且与之前的IBS症状相似。
在IBS和果糖吸收不良患者中,限制饮食中的果糖和/或果聚糖可能是症状改善的原因,这表明疗效通常归因于对吸收不良的短链碳水化合物的限制。